2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Oral Session

[O1] Oral Session 1　Gastrointestinal Cancer 1（Upper GI Tract）
【E】

Thu. Feb 17, 2022 9:30 AM - 11:00 AM Room 6 (Room D, 1F, Kyoto International Conference Center)

Chair：Taroh Satoh（Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine），Chin Kensho（Outpatient Chemotherapy Department, Cancer Institute Hospital of JFCR）
Discussant：Izuma Nakayama（Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the JFCR）

[O1-1] Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup

○Hiroki Hara1, Taroh Satoh2, Takashi Kojima3, Satoru Motoyama4, Takahiro Tsushima5, Yu Sunakawa6, Morihito Okada7, Aiyang Tao8, Ningning Ding8, Ken Kato9 (1.Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan, 2.Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan, 3.Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 4.Department of Esophageal Surgery, Akita University Hospital, Akita, Japan, 5.Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan, 6.Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan, 7.Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan, 8.BeiGene Ltd, Zhongguancun Life Science Park, Beijing, China, 9.Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password